Draft:Eidogen-Sertanty

From Wikipedia, the free encyclopedia
  • Comment: It's not clear how this meets WP:NCORP criteria from the citations. ~Liancetalk 22:00, 13 December 2023 (UTC)
  • Comment: Well done on creating the draft, and it may potentially meet the relevant requirements (including WP:GNG, WP:NCORP) but presently it is not clear that it does. As you may know, Wikipedia's basic requirement for entry is that the subject is notable. Essentially subjects are presumed notable if they have received significant coverage in multiple published secondary sources that are reliable, intellectually independent of each other, and independent of the subject. To properly create such a draft page, please see the articles ‘Your First Article’, ‘Referencing for Beginners’ and ‘Easier Referencing for Beginners’. Also, if you have any connection to the subject, including being paid, you have a conflict of interest that you must declare on your Talk page (to see instructions on how to do this please click the link). Please familiarise yourself with these pages before amending the draft. If you feel you can meet these requirements, then please make the necessary amendments before resubmitting the page. It would help our volunteer reviewers by identifying, on the draft's talk page, the WP:THREE best sources that establish notability of the subject. You may also wish to leave a note for me on my talk page and I would be happy to reassess. Cabrils (talk) 02:57, 16 November 2023 (UTC)


Eidogen-Sertanty, Inc.
Industry
Founded2003; 21 years ago (2003)
FounderSteven Muskal (CEO)
Headquarters
San Diego, California
,
United States
Websitewww.eidogen-sertanty.com

Eidogen-Sertanty is an American software company founded in 2003. Eidogen-Sertanty provides software[1] and content[2] and engages in collaborative services[3] which accelerate the drug discovery process.

Databases[edit]

  • Kinase Knowledgebase (KKB)[4][5] - Database of kinase structure-activity data.
  • Oncology Knowledgebase (OKB) - Database of oncological structure-activity data.
  • Target Informatics Platform (TIP)[6][7][8] - Protein structural informatics system and knowledgebase.

Sertanty and Eidogen-Sertanty[edit]

In 2005, Sertanty acquired Eidogen and was renamed to Eidogen-Sertanty, Inc[9]

See also[edit]

References[edit]

  1. ^ Schürer, Stephan C.; Tyagi, Prashant; Muskal, Steven M. (1 March 2005). "Prospective Exploration of Synthetically Feasible, Medicinally Relevant Chemical Space". Journal of Chemical Information and Modeling. 45 (2): 239–248. doi:10.1021/ci0496853. PMID 15807484.Vidović, Dušica; Muskal, Steven M.; Schürer, Stephan C. (21 December 2012). "Novel Kinase Inhibitors by Reshuffling Ligand Functionalities Across the Human Kinome". Journal of Chemical Information and Modeling. 52 (12): 3107–3115. doi:10.1021/ci3003842. PMID 23121521.Muskal, Steven M.; Jha, Sanjiv Kumar; Kishore, M. Phani; Tyagi, Prashant (1 September 2003). "A Simple and Readily Integratable Approach to Toxicity Prediction". Journal of Chemical Information and Computer Sciences. 43 (5): 1673–1678. doi:10.1021/ci034080c. PMID 14502502.
  2. ^ "Chemical Information Sources/SIRCh/Cheminformatics/Companies and Independent Institutions - Wikibooks, open books for an open world". en.wikibooks.org.
  3. ^ Muskal, Steven M.; Sliman, Joe; Kokai-Kun, John; Pimentel, Mark; Wacher, Vince; Gottlieb, Klaus (22 June 2016). "Lovastatin lactone may improve irritable bowel syndrome with constipation (IBS-C) by inhibiting enzymes in the archaeal methanogenesis pathway". F1000Research. 5: 606. doi:10.12688/f1000research.8406.3. PMC 4909102. PMID 27347377.Patel, Priya; Patel, Hiteshi; Vekariya, Dhara; Joshi, Chinmayi; Patel, Pooja; Muskal, Steven; Kothari, Vijay (5 July 2019). "Sonic Stimulation and Low Power Microwave Radiation Can Modulate Bacterial Virulence Towards Caenorhabditis elegans". Anti-Infective Agents. 17 (2): 150–162. doi:10.2174/2211352516666181102150049. S2CID 196993448.
  4. ^ Sharma, Rajan; Schürer, Stephan C.; Muskal, Steven M. (26 October 2016). "High quality, small molecule-activity datasets for kinase research". F1000Research. 5: 1366. doi:10.12688/f1000research.8950.1. PMC 4943296. PMID 27429748.
  5. ^ Hu, Jiaming; Allen, Bryce K.; Stathias, Vasileios; Ayad, Nagi G.; Schürer, Stephan C. (January 2024). "Kinome-Wide Virtual Screening by Multi-Task Deep Learning". International Journal of Molecular Sciences. 25 (5): 2538. doi:10.3390/ijms25052538. PMC 10932040. PMID 38473785.Allen, Bryce K.; Mehta, Saurabh; Ember, Stewart W. J.; Schonbrunn, Ernst; Ayad, Nagi; Schürer, Stephan C. (24 November 2015). "Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4". Scientific Reports. 5: 16924. Bibcode:2015NatSR...516924A. doi:10.1038/srep16924. PMC 4657038. PMID 26596901.Essegian, Derek J.; Chavez, Valery; Khurshid, Rabia; Merchan, Jaime R.; Schürer, Stephan C. (26 May 2023). "AI-Assisted chemical probe discovery for the understudied Calcium-Calmodulin Dependent Kinase, PNCK". PLOS Computational Biology. 19 (5): e1010263. Bibcode:2023PLSCB..19E0263E. doi:10.1371/journal.pcbi.1010263. PMC 10249896. PMID 37235579. Schürer, Stephan C.; Muskal, Steven M. (28 January 2013). "Kinome-wide Activity Modeling from Diverse Public High-Quality Data Sets". Journal of Chemical Information and Modeling. 53 (1): 27–38. doi:10.1021/ci300403k. PMC 3569091. PMID 23259810. Nicola, George; Kufareva, Irina; Ilatovskiy, Andrey V.; Abagyan, Ruben (March 2020). "Druggable exosites of the human kino-pocketome". Journal of Computer-Aided Molecular Design. 34 (3): 219–230. Bibcode:2020JCAMD..34..219N. doi:10.1007/s10822-019-00276-y. PMC 7082431. PMID 31925639.Wang, Huiwen; Qiu, Jiadi; Liu, Haoquan; Xu, Ying; Jia, Ya; Zhao, Yunjie (December 2019). "HKPocket: human kinase pocket database for drug design". BMC Bioinformatics. 20 (1): 617. doi:10.1186/s12859-019-3254-y. PMC 6884818. PMID 31783725.Jacoby, Edgar; Tresadern, Gary; Bembenek, Scott; Wroblowski, Berthold; Buyck, Christophe; Neefs, Jean-Marc; Rassokhin, Dmitrii; Poncelet, Alain; Hunt, Jeremy; van Vlijmen, Herman (June 2015). "Extending kinome coverage by analysis of kinase inhibitor broad profiling data". Drug Discovery Today. 20 (6): 652–658. doi:10.1016/j.drudis.2015.01.002. PMID 25596550.
  6. ^ Hambly, Kevin; Danzer, Joseph; Muskal, Steven; Debe, Derek A. (1 August 2006). "Interrogating the druggable genome with structural informatics". Molecular Diversity. 10 (3): 273–281. doi:10.1007/s11030-006-9035-3. PMID 17031532.
  7. ^ Palmer, Brian; Danzer, Joseph F.; Hambly, Kevin; Debe, Derek A. (1 July 2006). "StructSorter: A Method for Continuously Updating a Comprehensive Protein Structure Alignment Database". Journal of Chemical Information and Modeling. 46 (4): 1871–1876. doi:10.1021/ci0601012. PMID 16859318.
  8. ^ Jacoby, Edgar (11 May 2006). Chemogenomics: Knowledge-based Approaches To Drug Discovery. World Scientific. ISBN 978-1-78326-009-6.
  9. ^ "Eidogen And Sertanty Inc. Complete Merger To Become Eidogen-Sertanty, Inc". BioSpace."Drug Discovery Software | Eidogen-Sertanty". eidogen-sertanty.com.

External links[edit]

Retrieved from "https://en.wikipedia.org/w/index.php?title=Draft:Eidogen-Sertanty&oldid=1222711615"